1921
Volume 103, Issue 1_Suppl
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

For the past 10 years, the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE), funded by the Bill & Melinda Gates Foundation, has been supporting operational research to provide a stronger evidence base for controlling and moving toward elimination of schistosomiasis. The SCORE portfolio was developed and implemented with engagement from many stakeholders and sectors. Particular efforts were made to include endemic country neglected tropical disease program managers. Examples of the challenges we encountered include the need to balance rigor (e.g., conducting large cluster-randomized trials) with ensuring relevance to real-world settings, allowing for local contexts while standardizing key study aspects, adjusting to evolving technologies, and incorporating changing technologies into multiyear studies. The Schistosomiasis Consortium for Operational Research and Evaluation’s findings and data and the collected specimens will continue to be useful in the years to come. Our experiences and lessons learned can benefit both program managers and researchers conducting similar work in the future.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0786
2020-05-12
2020-09-22
Loading full text...

Full text loading...

/deliver/fulltext/14761645/103/1_Suppl/tpmd190786.html?itemId=/content/journals/10.4269/ajtmh.19-0786&mimeType=html&fmt=ahah

References

  1. Colley DG, Jacobson JA, Binder S, 2020. Schistosomiasis Consortium for Operational Research and Evaluation (SCORE): its foundations, development, and evolution. Am J Trop Med Hyg 103 (Suppl 1): 513.
    [Google Scholar]
  2. King CH et al., 2020. Impact of different mass drug administration strategies for gaining and sustaining control of Schistosoma mansoni and Schistosoma haematobium infection in Africa. Am J Trop Med Hyg 103 (Suppl 1): 1423.
    [Google Scholar]
  3. Kittur N et al., 2020. Discovering, defining, and summarizing persistent hotspots in SCORE studies. Am J Trop Med Hyg 103 (Suppl 1): 2429.
    [Google Scholar]
  4. Colley DG et al., 2020. Evaluation, validation, and recognition of the point-of-care circulating cathodic antigen, urine-based assay for mapping Schistosoma mansoni infections. Am J Trop Med Hyg 103 (Suppl 1): 4249.
    [Google Scholar]
  5. Corstjens PLAM et al., 2020. Circulating Anodic Antigen (CAA): a highly sensitive diagnostic biomarker to detect active Schistosoma infections–improvements and use during SCORE. Am J Trop Med Hyg 103 (Suppl 1): 5057.
    [Google Scholar]
  6. Colley DG, Secor WE, 2007. A schistosomiasis research agenda. PLoS Negl Trop Dis 1: e32.
    [Google Scholar]
  7. Zachariah R, Harries AD, Ishikawa N, Rieder HL, Bissell K, Laserson K, Massaquoi M, Van Herp M, Reid T, 2009. Operational research in low-income countries: what, why, and how? Lancet Infect Dis 9: 711717.
    [Google Scholar]
  8. WHO, 2006. Preventive Chemotherapy in Human Helminthiasis: Coordinated Use of Anthelminthic Drugs in Control Interventions: A Manual for Health Professionals and Programme Managers. Geneva, Switzerland: World Health Organization.
    [Google Scholar]
  9. Colley DG et al., 2020. Contributions of the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) to Schistosomiasis control and elimination: key findings and messages for future goals, thresholds, and operational research. Am J Trop Med Hyg 103 (Suppl 1): 125134.
    [Google Scholar]
  10. Ezeamama AE et al., 2016. Gaining and sustaining schistosomiasis control: study protocol and baseline data prior to different treatment strategies in five African countries. BMC Infect Dis 16: 229.
    [Google Scholar]
  11. WHO, 2013. Schistosomiasis: Progress Report 2001–2011, Strategic Plan 2012–2020. Geneva, Switzerland: World Health Organization.
    [Google Scholar]
  12. King CH, Kittur N, Wiegand RE, Shen Y, Ge Y, Whalen CC, Campbell C, Hattendorf J, Binder S, 2020. Challenges in protocol development and interpretation of the Schistosomiasis Consortium for Operational Research and Evaluation intervention studies. Am J Trop Med Hyg 103 (Suppl 1): 3641.
    [Google Scholar]
  13. Campbell CH Jr. et al., 2020. SCORE operational research on moving toward interruption of schistosomiasis transmission. Am J Trop Med Hyg 103 (Suppl 1): 5865.
    [Google Scholar]
  14. Binder S et al., 2020. Lessons learned in conducting mass drug administration for schistosomiasis control and measuring coverage in an operational research setting. Am J Trop Med Hyg 103 (Suppl 1): 105113.
    [Google Scholar]
  15. Campbell SJ et al., 2018. The COUNTDOWN study protocol for expansion of mass drug administration strategies against schistosomiasis and soil-transmitted helminthiasis in Ghana. Trop Med Infect Dis 3: E10.
    [Google Scholar]
  16. Fenwick A, Jourdan P, 2016. Schistosomiasis elimination by 2020 or 2030? Int J Parasitol 46: 385388.
    [Google Scholar]
  17. Secor WE, Colley DG, 2018. When should the emphasis on schistosomiasis control move to elimination? Trop Med Infect Dis 3: E85.
    [Google Scholar]
  18. Barenbold O et al., 2018. Translating preventive chemotherapy prevalence thresholds for Schistosoma mansoni from the Kato-Katz technique into the point-of-care circulating cathodic antigen diagnostic test. PLoS Negl Trop Dis 12: e0006941.
    [Google Scholar]
  19. Clements MN et al., 2018. Latent class analysis to evaluate performance of point-of-care CCA for low-intensity Schistosoma mansoni infections in Burundi. Parasit Vectors 11: 111.
    [Google Scholar]
  20. Ortu G et al., 2017. Countrywide reassessment of Schistosoma mansoni infection in Burundi using a urine-circulating cathodic antigen rapid test: informing the national control program. Am J Trop Med Hyg 96: 664673.
    [Google Scholar]
  21. Webster JP et al., 2020. Parasite population genetic contributions to the Schistosomiasis Consortium for Operational Research and Evaluation within Sub-Saharan Africa. Am J Trop Med Hyg 103 (Suppl 1): 8091.
    [Google Scholar]
  22. Mwinzi PN, Kittur N, Ochola E, Cooper PJ, Campbell CH Jr., King CH, Colley DG, 2015. Additional evaluation of the point-of-contact circulating cathodic antigen assay for Schistosoma mansoni infection. Front Public Health 3: 48.
    [Google Scholar]
  23. Haggag AA, Rabiee A, Abd Elaziz KM, Campbell CH, Colley DG, Ramzy RMR, 2019. Thirty-day daily comparisons of Kato-Katz and CCA assays of 45 Egyptian children in areas with very low prevalence of Schistosoma mansoni. Am J Trop Med Hyg 100: 578583.
    [Google Scholar]
  24. Castro N, Medina R, Sotelo J, Jung H, 2000. Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob Agents Chemother 44: 29032904.
    [Google Scholar]
  25. Muhumuza S, Olsen A, Katahoire A, Nuwaha F, 2015. Reduced uptake of mass treatment for schistosomiasis control in absence of food: beyond a randomized trial. BMC Infect Dis 15: 423.
    [Google Scholar]
  26. Omedo MO, Matey EJ, Awiti A, Ogutu M, Alaii J, Karanja DM, Montgomery SP, Secor WE, Mwinzi PN, 2012. Community health workers’ experiences and perspectives on mass drug administration for schistosomiasis control in western Kenya: the SCORE Project. Am J Trop Med Hyg 87: 10651072.
    [Google Scholar]
  27. Center NS, 2019. Coverage Evaluation Surveys. Available at: https://www.ntdsupport.org/resources/coverage-survey-builder-coverage-evaluations. Accessed September 26, 2019.
    [Google Scholar]
  28. World Health Organization, 2016. Coverage Evaluation Surveys for Preventive Chemotherapy: Field Guide for Implementation. Available at: https://www.ntdsupport.org/sites/default/files/uploads/docs/resources/Coverage%20Evaluation%20Guidelines%20Final%20Draft_DEC%202016_clean_corrected%2024OCT18.docx. Accessed September 26, 2019.
    [Google Scholar]
  29. Knopp S et al., 2016. Praziquantel coverage in schools and communities targeted for the elimination of urogenital schistosomiasis in Zanzibar: a cross-sectional survey. Parasit Vectors 9: 5.
    [Google Scholar]
  30. Allan F et al., 2020. Snail-related contributions from the Schistosomiasis Consortium for Operational Research and Evaluation program including xenomonitoring, focal mollusciciding, biological control, and modeling. Am J Trop Med Hyg 103 (Suppl 1): 6679.
    [Google Scholar]
  31. Person B, 2012. A Human Centered Design Project for Schistosomiasis Elimination in Zanzibar (Unguja and Pemba Islands) - Formative Research Findings. Atlanta, GA: Centers for Disease Control and Prevention, 137.
    [Google Scholar]
  32. King CH et al., 2020. SCORE studies on the impact of drug treatment on morbidity due to Schistosoma mansoni and Schistosoma haematobium infection. Am J Trop Med Hyg 103 (Suppl 1): 3035.
    [Google Scholar]
  33. Worrell CM, Bartoces M, Karanja DM, Ochola EA, Matete DO, Mwinzi PN, Montgomery SP, Secor WE, 2015. Cost analysis of tests for the detection of Schistosoma mansoni infection in children in western Kenya. Am J Trop Med Hyg 92: 12331239.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0786
Loading
/content/journals/10.4269/ajtmh.19-0786
Loading

Data & Media loading...

  • Received : 23 Oct 2019
  • Accepted : 15 Jan 2020
  • Published online : 12 May 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error